finanzen.net
12.09.2019 12:30
Bewerten
(0)

I-Mab Biopharma Expands Global Team, Appoints Neil K. Warma As General Manager of I-Mab U.S.

SHANGHAI and GAITHERSBURG, Md., Sept. 12, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announced the appointment of Mr. Neil K. Warma as General Manager of I-Mab Biopharma U.S., Limited on September 3rd. Mr. Warma will lead the Company's effort to expand the R&D and business operations in the U.S. Mr. Warma will be based in the U.S.

Mr. Neil K. Warma

Mr. Warma has over 25 years of experience in the healthcare industry across the globe. Prior to joining I-Mab, he was President and CEO of Opexa Therapeutics (NASDAQ: OPXA), where he led the development of the company's personalized cell therapy platform and oversaw its advance through clinical development. Mr. Warma also held key management roles at Novartis as Head of Global Pharma Policy and in Global Marketing. In the years before, he was the CEO of Viron Therapeutics, and, prior to that was President and Co-founder of MedExact.

"We are very excited to have Neil in our executive team at this critical juncture of the Company's rapid development to grow the global presence," said Dr. Jingwu Zang, Founder and Chairman at I-Mab. "Neil's extensive global experiences and proven track record in the pharma and biotech industry will greatly strengthen our global capabilities and leadership to become a global player in our journey moving toward a fully-integrated, global biopharmaceutical company."

"I am thrilled to join I-Mab, an innovative biopharmaceutical company with a successful track record and reputation for advancing transformational medicines with First-in-Class and Best-in-Class potential," Mr. Warma expressed. "I-Mab has a very exciting and rich pipeline of novel drug candidates, with several in late-stage clinical development. Expansion of the business in the U.S. and globally is a natural evolution for I-Mab and I look forward to leading these efforts."

Mr. Warma obtained an honors degree specializing in neuroscience from the University of Toronto and an International MBA from the Schulich School of Business at York University in Toronto. 

About I-Mab:

I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing biologics of first-in-class or best-in-class potential in the therapeutic areas of immuno-oncology and autoimmune diseases. I-Mab's mission is to bring transformational medicines to patients through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to become a fully integrated end-to-end global biopharmaceutical company with cutting-edge discovery platforms, proven preclinical and clinical development expertise, and world-class GMP manufacturing capabilities. I-Mab is well-recognized by capital markets to have successfully raised over US$400 million in equity financing since its establishment in 2016. Its recent USD$200 million Series C financing represents one of the largest amounts ever raised by a biotech company in China. For more information, please visit the Company's website at www.i-mabbiopharma.com.

Contact:
Jielun Zhu, CFO
jielun.zhu@i-mabbiopharma.com

 Neil K. Warma, General Manager, I-Mab Biopharma U.S., Ltd.
neil.warma@i-mabbiopharma.com

Amanda Dai, Associate Director of Public Relations
zhenhua.dai@i-mabbiopharma.com

I-MAB Logo (PRNewsfoto/I-Mab Biopharma)

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/i-mab-biopharma-expands-global-team-appoints-neil-k-warma-as-general-manager-of-i-mab-us-300916858.html

SOURCE I-Mab Biopharma

Werbung
Werbung
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX geht kaum verändert ins Wochenende -- US-Börsen schließen im Minus -- CoBa will Stellen streichen -- Hoffnung auf Bewegung im Brexit-Streit -- K+S, Thomas Cook, Roche, HHLA im Fokus

Deutz kappt Gewinnprognose. Trump sieht Fortschritte bei Handelsgesprächen mit China. OSRAM-Aufsichtsratschef verkauft Aktien ebenfalls nicht an ams. Capital Group stockt E.ON-Anteile auf über 10 Prozent auf. TRATON-Beteiligung Navistar erwartet höhere Marge. Amazon startet Klimainitiative - 100.000 Elektro-Lieferwagen bestellt.

Die 5 beliebtesten Top-Rankings

Apple nicht mehr Platz 1
Das sind die wertvollsten Unternehmen der Welt 2019
Die wertvollsten Fußballvereine der Welt 2019
Welcher Club ist am wertvollsten?
Die 12 toten Topverdiener 2019
Diese Legenden sind die bestbezahlten Toten der Welt
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
Big-Mac-Index
In welchen Ländern kostet der Big Mac wie viel?
mehr Top Rankings

Umfrage

Wo sehen Sie den DAX Ende 2019?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Microsoft Corp.870747
Daimler AG710000
Scout24 AGA12DM8
Apple Inc.865985
Wirecard AG747206
Allianz840400
Amazon906866
E.ON SEENAG99
BMW AG519000
Thomas CookA0MR3W
BASFBASF11
NEL ASAA0B733
TeslaA1CX3T
adidasA1EWWW